Hiroki A. Ueyama

Hiroki A. Ueyama

Auto-generated profile, based on publicly available information

Hiroki A. Ueyama

Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
TSTomonari Shimoda
Tomonari Shimoda
HUHiroki A. Ueyama
Hiroki A. Ueyama
YMYoshihisa Miyamoto
Yoshihisa Miyamoto
AWAtsuyuki Watanabe
Atsuyuki Watanabe
HGHiroshi Gotanda
Hiroshi Gotanda
TKToshiki Kuno
Toshiki Kuno
BACKGROUND: Evidence is limited as to whether outcomes differ between patients with tricuspid regurgitation (TR) treated with tricuspid transcatheter edge-to-edge repair (T-TEER) versus surgical tricuspid valve repair. We aimed to compare outcomes between these 2 approaches. METHODS: We analyzed the data on Medicare fee-for-service beneficiaries aged 65 to 99 years with TR who underwent T-TEER or isolated surgical repair between July 2016 and December 2020. The primary outcome was 2-year all-cause mortality. Other outcomes included in-hospital mortality and permanent pacemaker implantation as well as 2-year heart failure hospitalization and tricuspid valve reintervention. A propensity score matching weight analysis was used to adjust for potential confounders. RESULTS: A total of 1143 patients were included (409 T-TEER versus 734 surgery). The proportion of T-TEER cases increased from 2% in the third quarter of 2016 to 67% in the last quarter of 2020 among all isolated TR procedures. After adjustment for potential confounders, we found no evidence that 2-year all-cause mortality differs between patients treated with T-TEER versus surgical repair (adjusted hazard ratio, 0.84 [95% CI, 0.63–1.13]). Patients treated with T-TEER experienced lower in-hospital mortality (2.5% versus 12.5%, P <0.001) and permanent pacemaker implantation rates (0.0% versus 12.7%, P <0.001) than those treated by surgical repair. At 2 years, we found no differences in heart failure hospitalizations, but tricuspid valve reinterventions were more frequent in the T-TEER group (subdistribution hazard ratio, 8.03 [95% CI, 2.87–22.48]). CONCLUSIONS: Among Medicare beneficiaries with TR, the 2-year mortality rate was comparable between T-TEER and surgical repair. T-TEER showed advantages in perioperative outcomes, including lower in-hospital mortality and pacemaker implantation rates, whereas tricuspid valve reinterventions were more frequent in the T-TEER group. Further studies are necessary to refine indications, patient selections, and optimal timing for intervention with either treatment strategy.

1 April 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HUHiroki Ueyama
Hiroki Ueyama
TKToshiki Kuno
Toshiki Kuno
TATomo Ando
Tomo Ando
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
JFJohn Fox
John Fox
HTHisato Takagi
Hisato Takagi

10 February 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DSDaryoush Samim
Daryoush Samim
PSPaul Sorajja
Paul Sorajja
JLJonas Lanz
Jonas Lanz
LSLukas Stolz
Lukas Stolz
Domenico AngellottiDomenico Angellotti
Domenico Angellotti
Fabien PrazFabien Praz
Fabien Praz

6 January 2025 in JACC
Verified
Journal Article
Closed access
HUHiroki A. Ueyama
Hiroki A. Ueyama
KAKEITARO AKITA
KEITARO AKITA
YKYuko Kiyohara
Yuko Kiyohara
HTHisato Takagi
Hisato Takagi
ABAlexandros Briasoulis
Alexandros Briasoulis
DBDeepak L Bhatt
Deepak L Bhatt

13 January 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
GTGiuseppe Tarantini
Giuseppe Tarantini
GTGilbert H.L. Tang
Gilbert H.L. Tang
TPThomas Pilgrim
Thomas Pilgrim
WKWon-K. Kim
Won-K. Kim
AGAdam Greenbaum
Adam Greenbaum
LFLuca Nai Fovino
Luca Nai Fovino
Lifetime treatment of aortic valve disease is a matter of increasing debate. Although the risks of a second aortic valve intervention are recognized, little attention has been given to the challenges of a third. This study delves into the clinical characteristics, indications, and outcomes of patients undergoing 3 aortic valve interventions. The THIRD (THree aortIc Reinterventions for valve Disease) registry is a retrospective multicenter, international study of patients who underwent a third procedure on the aortic valve, either surgically or transcatheter-based. Patients undergoing 2 aortic procedures during the same hospital admission were excluded. Baseline characteristics, timing, and mode of bioprosthetic failure, sequence of the procedures, and clinical outcomes were adjudicated according to the Valve Academic Research Consortium criteria. A total of 51 patients from 11 centers were enrolled in this study. Median follow-up time was 565 (314-1,560) days. Eighteen patients (35%) underwent surgical aortic valve replacement (SAVR), and 33 of 51 patients (65%) underwent transcatheter aortic valve replacement (TAVR) as the third intervention. Mean age was 69 ± 14 years, 20 of 51 patients (39%) were female. STS score was 5.0% (Q1-Q3: 3.3%-7.0%). In all TAVR cases, the indication for the first intervention was severe aortic stenosis, as was the indication in 31 of 45 (69%) of SAVR cases (33% bicuspid). The most prevalent procedure sequence was SAVR-SAVR-TAVR (19/51, 37%), followed by SAVR-SAVR-SAVR (10/51, 20%) and SAVR-TAVR-TAVR (10/51, 20%). TAVR-TAVR-TAVR was performed in 4 of 51 cases (8%). The primary indications for a third intervention included structural valve deterioration (SVD) (39/51, 76%), non-SVD (8/51, 16%), and endocarditis (2/51, 4%). Excluding patients with a mechanical prosthesis, predictors of SAVR as third intervention included a lower STS score (OR: 0.58; 95% CI: 0.34-0.98; P = 0.04) and the presence of moderate or severe prosthesis-patient mismatch (OR: 44.8; 95% CI: 2.41-122.00; P = 0.01). Thirty-day device success was 85% for TAVR and 94% for SAVR. In the THIRD registry, SVD emerged as the predominant indication for a third aortic valve procedure. The most frequent procedure sequence was SAVR-SAVR-TAVR, whereas TAVR-TAVR-TAVR was less common. Although the short-term outcomes in our selected cohort were favorable, further investigation is needed.

15 November 2024 in JACC
Verified
Journal Article
Closed access
HUHiroki A. Ueyama
Hiroki A. Ueyama
KKKevin F. Kennedy
Kevin F. Kennedy
JRJennifer A. Rymer
Jennifer A. Rymer
ASAlexander T. Sandhu
Alexander T. Sandhu
TKToshiki Kuno
Toshiki Kuno
SKShun Kohsaka
Shun Kohsaka